Reports Q3 revenue $1.07B, consensus $1.12B. “I am pleased to report that in the fiscal third quarter Catalent returned to growth, including double-digit non-COVID year-on-year revenue growth. We also continued our momentum in both the Biologics segment and the Pharma and Consumer Health segment, which drove an increase in consolidated sequential revenue and adjusted EBITDA margin for the second consecutive quarter, as we continue to make progress toward our near-term margin objectives. Additionally, we achieved record third quarter non-COVID customer wins, and our non-COVID customer wins in the first three quarters of the fiscal year increased double digits over the prior year. This momentum reflects the value of our diverse portfolio to our customers and supports our expectations for continued future growth,” said Alessandro Maselli, President and Chief Executive Officer of Catalent, Inc.